Literature DB >> 18161916

AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.

K J Schmitz1, H Lang, J Wohlschlaeger, G C Sotiropoulos, H Reis, K W Schmid, H A Baba.   

Abstract

Intrahepatic cholangiocarcinomas (ICC) are neoplasms that originate from cholangiocytes and can occur at any level of the biliary tree. Surgical resection is the current therapy of choice for this highly aggressive cancer. However, the 5-year survival still is poor, with high recurrence rates. Due to the intrahepatic growth a significant proportion of patients present with advanced disease and are not candidates for curative surgery or transplantation. The existing palliative options are of limited benefit and there is a great necessity for novel therapeutic options. In this article we review the role of the phosphoinositide 3-kinase(PI3K)/AKT and extracellular regulated kinase (ERK) signaling pathways in ICC and present new data on the prognostic value of these protein kinases. Finally, we discuss future upcoming therapeutic options based on targeting these signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18161916      PMCID: PMC4611285          DOI: 10.3748/wjg.v13.i48.6470

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  58 in total

1.  Phosphorylation and regulation of Raf by Akt (protein kinase B).

Authors:  S Zimmermann; K Moelling
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

2.  Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable.

Authors:  Y H Min; J I Eom; J W Cheong; H O Maeng; J Y Kim; H K Jeung; S T Lee; M H Lee; J S Hahn; Y W Ko
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

3.  Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.

Authors:  J Xing; D D Ginty; M E Greenberg
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

Review 4.  PI3K: downstream AKTion blocks apoptosis.

Authors:  T F Franke; D R Kaplan; L C Cantley
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

5.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.

Authors:  W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

6.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Authors:  John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

7.  Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.

Authors:  Anna Vilgelm; Zenglin Lian; Hong Wang; Stephen L Beauparlant; Andres Klein-Szanto; Lora Hedrick Ellenson; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669.

Authors:  I C Northwood; F A Gonzalez; M Wartmann; D L Raden; R J Davis
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

Review 9.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

10.  Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method.

Authors:  A Nonomura; G Ohta; Y Nakanuma; R Izumi; Y Mizukami; F Matsubara; M Hayashi; K Watanabe; N Takayanagi
Journal:  Liver       Date:  1988-06
View more
  36 in total

1.  Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia.

Authors:  Anatoliy I Masyuk; Bing Q Huang; Christopher J Ward; Sergio A Gradilone; Jesus M Banales; Tatyana V Masyuk; Brynn Radtke; Patrick L Splinter; Nicholas F LaRusso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-15       Impact factor: 4.052

Review 2.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

3.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

4.  Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.

Authors:  Shanshan Zhang; Xinhua Song; Dan Cao; Zhong Xu; Biao Fan; Li Che; Junjie Hu; Bin Chen; Mingjie Dong; Maria G Pilo; Antonio Cigliano; Katja Evert; Silvia Ribback; Frank Dombrowski; Rosa M Pascale; Antonio Cossu; Gianpaolo Vidili; Alberto Porcu; Maria M Simile; Giovanni M Pes; Gianluigi Giannelli; John Gordan; Lixin Wei; Matthias Evert; Wenming Cong; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2017-07-19       Impact factor: 25.083

5.  Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.

Authors:  Florian Ewald; Dominik Nörz; Astrid Grottke; Bianca T Hofmann; Björn Nashan; Manfred Jücker
Journal:  Invest New Drugs       Date:  2014-08-26       Impact factor: 3.850

6.  Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.

Authors:  Fanyin Meng; Sharon DeMorrow; Julie Venter; Gabriel Frampton; Yuyan Han; Heather Francis; Holly Standeford; Shanika Avila; Kelly McDaniel; Matthew McMillin; Syeda Afroze; Micheleine Guerrier; Morgan Quezada; Debolina Ray; Lindsey Kennedy; Laura Hargrove; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-03-06       Impact factor: 4.052

Review 7.  Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.

Authors:  Daniel H Ahn; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 8.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

9.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

10.  Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.

Authors:  Qinglong Li; Zhulin Yang
Journal:  J Exp Clin Cancer Res       Date:  2009-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.